Linda Wittkop

List of Publications by Year
in descending order

114	2,473	236833	233338
papers	citations	25 h-index	45 g-index

117	117	117	4171
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
2	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Medicine, 2012, 9, e1001194.	3.9	145
3	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clinical Microbiology and Infection, 2022, 28, 163-177.	2.8	120
4	Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. Clinical Cancer Research, 2017, 23, 1586-1597.	3.2	117
5	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
6	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virusâ€“Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases, 2017, 65, 959-966.	2.9	75
7	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	1.6	75
8	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
9	The negative impact of <scp>HBV</scp>/<scp>HCV</scp> coinfection on cirrhosis and its consequences. Alimentary Pharmacology and Therapeutics, 2017, 46, 1054-1060.	1.9	66
10	HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. Journal of Antimicrobial Chemotherapy, 2010, 65, 1262-1269.	1.3	63
11	Effect of Cytomegalovirus-Induced Immune Response, Self Antigenâ€“Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1â€“Infected Patients: The ANRS CO3 Aquitaine Cohort. Journal of Infectious Diseases, 2013, 207, 622-627.	1.9	61
12	Multimorbidity, age-related comorbidities and mortality. Aids, 2018, 32, 1651-1660.	1.0	57
13	All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virusâ€“coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13â€“HEPAVIH Cohort. Clinical Infectious Diseases, 2016, 63, 763-770.	2.9	52
14	Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. Aids, 2015, 29, 2099-2108.	1.0	47
15	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients â€“ French ANRS CO13 HEPAVIH cohort. Journal of Hepatology, 2017, 67, 23-31.	1.8	45
16	Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cellular Microbiology, 2010, 12, 962-975.	1.1	38
17	Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. Aids, 2015, 29, 1821-1830.	1.0	37
18	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of Antimicrobial Chemotherapy, 2009, 63, 1251-1255.	1.3	33

#	Article	IF	Citations
19	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical Trials, 2010, 7, 19-35.	0.7	33
20	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV,the, 2014, 1, e119-e126.	2.1	32
21	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	1.1	30
22	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Digestive and Liver Disease, 2011, 43, 975-983.	0.4	28
23	Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Coâ€infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or Endâ€Stage Liver Disease as Compared to HCV Monoâ€infected Patients. Hepatology, 2019, 70, 939-954.	3.6	28
24	Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Medicine, 2011, 12, 506-509.	1.0	27
25	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Journal of Hepatology, 2017, 67, 1157-1167.	1.8	25
26	Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study). Antiviral Therapy, 2008, 13, 271-280.	0.6	25
27	Red scrotum syndrome. Journal of Dermatological Case Reports, 2011, 5, 38-41.	1.1	24
28	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Current Opinion in HIV and AIDS, 2016, 11, 521-526.	1.5	24
29	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virusâ€coâ€infected patients (<scp>ANRS CO</scp>13â€<scp>HEPAVIH</scp>). Journal of Viral Hepatitis, 2018, 25, 171-179.	1.0	23
30	Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. Journal of Antimicrobial Chemotherapy, 2010, 65, 434-437.	1.3	22
31	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	1.3	22
32	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Trials, 2020, 21, 846.	0.7	21
33	Increased mortality in HIV/HCV-coinfected compared toÂHCV-monoinfected patients in the DAA era due to non-liver-related death. Journal of Hepatology, 2021, 74, 37-47.	1.8	21
34	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
35	Analysis of RT Sequences of Subtype C HIV-Type 1 Isolates from Indian Patients at Failure of a First-Line Treatment According to Clinical and/or Immunological WHO Guidelines. AIDS Research and Human Retroviruses, 2010, 26, 343-350.	0.5	19
36	Mortality in migrants living with HIV in western Europe (1997â€“2013): a collaborative cohort study. Lancet HIV,the, 2015, 2, e540-e549.	2.1	19

#	Article	IF	Citations
37	Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. Aids, 2017, 31, 253-262.	1.0	19
38	No significant effect of cannabis use on the count and percentage of circulating CD4 Tâ€cells in HIVâ€HCV coâ€infected patients (ANRS CO13â€HEPAVIH French cohort). Drug and Alcohol Review, 2017, 36, 227-238.	1.1	18
39	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort). Nutrients, 2018, 10, 705.	1.7	18
40	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	2.9	18
41	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
42	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coâ€infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	1.0	15
43	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Aids, 2017, 31, 835-846.	1.0	14
44	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. Aids, 2018, 32, 1361-1367.	1.0	14
45	A French cohort for assessing COVID-19 vaccine responses in specific populations. Nature Medicine, 2021, 27, 1319-1321.	15.2	14
46	Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy. Antiviral Therapy, 2013, 18, 723-727.	0.6	12
47	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). AIDS and Behavior, 2020, 24, 1069-1084.	1.4	12
48	Triple therapy with boceprevir or telaprevir in a <scp>E</scp>uropean cohort of cirrhotic <scp>HIV</scp>/<scp>HCV</scp> genotype 1â€coinfected patients. Liver International, 2015, 35, 2090-2099.	1.9	10
49	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World Journal of Hepatology, 2018, 10, 856-866.	0.8	10
50	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. Journal of Hepatology, 2018, 68, 845-847.	1.8	9
51	Prognostic factors of survival in <scp>HIV</scp>/<scp>HCV</scp> coâ€infected patients with hepatocellular carcinoma: The <scp>CARCINOVIC</scp> Cohort. Liver International, 2019, 39, 136-146.	1.9	9
52	Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort). European Journal of Gastroenterology and Hepatology, 2019, 31, 1508-1517.	0.8	9
53	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	1.5	9
54	Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antiviral Therapy, 2008, 13, 271-9.	0.6	9

#	Article	IF	Citations
55	P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER. Journal of Hepatology, 2015, 62, S631-S632.	1.8	8
56	Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. PLoS ONE, 2019, 14, e0211286.	1.1	8
57	Elevated Fatty Liver Index as a Risk Factor for Allâ€Cause Mortality in Human Immunodeficiency Virusâ€“Hepatitis C Virusâ€“Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology, 2020, 71, 1182-1197.	3.6	8
58	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS and Behavior, 2021, 25, 4141-4153.	1.4	8
59	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. HIV Medicine, 2018, 19, 42-48.	1.0	8
60	Predictors of CD4+ T-Cell Counts of HIV Type 1â€“Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
61	Short article: Fatigue in the long term after HCV treatment in HIVâ€“HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). European Journal of Gastroenterology and Hepatology, 2016, 28, 1003-1007.	0.8	7
62	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children â€“ a EuroCoord-CHAIN-EPPICC joint project. BMC Infectious Diseases, 2016, 16, 654.	1.3	7
63	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRSÂCO13 HEPAVIH). Journal of Hepatology, 2020, 72, 588-591.	1.8	7
64	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). Nutrients, 2020, 12, 2532.	1.7	7
65	Doubleâ€blind , randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderateâ€toâ€severe relapses of multiple sclerosis. Journal of Clinical Apheresis, 2020, 35, 281-289.	0.7	7
66	T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults. BMC Immunology, 2014, 15, 13.	0.9	6
67	Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada. Aids, 2015, 30, 1.	1.0	6
68	Activation, senescence and inflammation markers in HIV patients. Aids, 2017, 31, 1119-1128.	1.0	6
69	Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors. BMC Medical Research Methodology, 2018, 18, 159.	1.4	6
70	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Journal of the International AIDS Society, 2018, 21, e25200.	1.2	6
71	Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohortâ€™s QuAliV ancillary study. Health and Quality of Life Outcomes, 2020, 18, 220.	1.0	6
72	Life after hepatitis C cure in HIVâ€infected people who inject drugs and men who have sex with men treated with directâ€acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2020, 27, 1462-1472.	1.0	6

#	Article	IF	Citations
73	Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clinical Infectious Diseases, 2021, 72, e215-e223.	2.9	6
74	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Review of Anti-Infective Therapy, 2021, 19, 1147-1156.	2.0	6
75	HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Journal of Clinical Virology, 2015, 73, 32-35.	1.6	5
76	Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PLoS ONE, 2017, 12, e0169164.	1.1	5
77	Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort). Journal of Hepatology, 2018, 68, S142-S143.	1.8	5
78	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. Aids, 2020, 34, 953-954.	1.0	5
79	Mathematical analysis of a HIV model with quadratic logistic growth term. Discrete and Continuous Dynamical Systems - Series B, 2012, 17, 2359-2385.	0.5	5
80	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Medical Research Methodology, 2008, 8, 68.	1.4	4
81	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
82	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	1.0	4
83	Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. European Journal of Gastroenterology and Hepatology, 2019, 31, 1387-1396.	0.8	4
84	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). European Journal of Gastroenterology and Hepatology, 2017, 29, 786-791.	0.8	4
85	LP20 : Safety and efficacy of all-oral daa regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort. Journal of Hepatology, 2015, 62, S273-S274.	1.8	3
86	Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort. PLoS ONE, 2018, 13, e0208657.	1.1	3
87	Evolution of patientsâ€™ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS ONE, 2018, 13, e0199874.	1.1	3
88	Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz549.	0.4	3
89	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	2.6	3
90	LP23 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIVâ€“HCV co-infection: interim analysis of a French multicenter compassionate use program. Journal of Hepatology, 2015, 62, S275.	1.8	2

#	Article	IF	Citations
91	Rapid Adenovirus typing method for species identification. Journal of Virological Methods, 2017, 249, 156-160.	1.0	2
92	Impaired patientâ€reported outcomes persist in <scp>HIV</scp>â€<scp>HCV</scp> coâ€infected patients and in cirrhotic patients despite <scp>HCV</scp> clearance. Journal of Viral Hepatitis, 2018, 25, 314-315.	1.0	2
93	No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	2
94	Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort. Clinical Infectious Diseases, 2020, 71, 2536-2538.	2.9	2
95	Direct, indirect and total effect of HIV coinfection on the risk of nonâ€liverâ€related cancer in hepatitis C virusâ€infected patients treated by directâ€acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935.	1.0	2
96	Postâ€HCV cure selfâ€reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). Journal of Viral Hepatitis, 2021, 28, 1665-1667.	1.0	2
97	Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation. JMIR Formative Research, 2019, 3, e15013.	0.7	2
98	56 DYNAMICS OF HCV QUASISPECIES DURING TELAPREVIR TREATMENT DISSECTED USING ULTRA-DEEP PYROSEQUENCING: TREATMENT FAILURE IN 100% OF GENOTYPE 1A PATIENTS. Journal of Hepatology, 2012, 56, S25.	1.8	1
99	P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort â€“ ANRS CO22 hepather. Journal of Hepatology, 2015, 62, S488-S489.	1.8	1
100	End-Stage Liver Disease in HIV Infection: An Avoidable Burden?. Clinical Infectious Diseases, 2016, 63, ciw537.	2.9	1
101	Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virusâ€“Coinfected Individuals. Clinical Infectious Diseases, 2018, 66, 983-984.	2.9	1
102	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). American Journal of Gastroenterology, 2018, 113, 1729-1732.	0.2	1
103	Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIVâ€“HCV co-infected individuals. Clinical and Experimental Immunology, 2021, 204, 107-124.	1.1	1
104	Risk of severe clinical events after sustained virological response following directâ€acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV Medicine, 2021, 22, 791-804.	1.0	1
105	Statin use and risk of severe bacterial infection in a population living with HIV: prospective cohort study of the ANRS CO3 Aquitaine Cohort 2000â€“2018. Clinical Microbiology and Infection, 2021, 27, 1301-1307.	2.8	1
106	Tobacco use in people living with HIV: The need for complementary descriptive data to see beyond the smoke screen. International Journal of Drug Policy, 2022, 102, 103616.	1.6	1
107	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. Journal of Cannabis Research, 2022, 4, .	1.5	1
108	1025 THE GENETIC BARRIER MODULATES THE IMMUNE ESCAPE POTENTIAL OF HBV GENOTYPES. Journal of Hepatology, 2010, 52, S396-S397.	1.8	0

#	Article	IF	Citations
109	708 OVERLAPPING STRUCTURE OF HBV GENOME AND IMMUNE SELECTING PRESSURE ARE THE MAIN DRIVING FORCES FOR HBV EVOLUTION. Journal of Hepatology, 2011, 54, S284-S285.	1.8	0
110	P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER. Journal of Hepatology, 2015, 62, S630-S631.	1.8	0
111	HIV/HCV-coinfected cirrhotic patients are no longer at higher risk of hepatocellular carcinoma or end-stage liver disease as compared to HCV-monoinfected patients (ANRS CO12 CirVir and ANRS CO13) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	0
112	Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis. Journal of Hepatology, 2018, 68, S175-S176.	1.8	0
113	Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients. European Journal of Public Health, 2019, 29, .	0.1	0
114	Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 461-466.	0.9	0